AstraZeneca (STO:AZN) (LSE:AZN) Third quarter revenue increased by 10 percent at constant exchange rates (CER) to $8,200 million.
-US sales of Toprol-XL, benefiting from withdrawal of generic products, accounted for 3 percent of global revenue growth at CER.
-US sales of Novel Influenza A (H1N1) vaccine totalled $152 million in the third quarter, accounting for 2 percent of global revenue growth at CER. -Emerging Markets revenue was up 15 percent at CER; on track for double-digit growth for the full year.
Core operating profit in the third quarter increased by 29 percent at CER to $3,609 million on revenue growth and operational efficiencies. Core EPS in the third quarter increased by 27 percent at CER to $1.68.
Reported EPS in the third quarter increased by 22 percent at CER to $1.46.
-Agreement in principle reached with the US Attorney’s Office in Philadelphia to resolve its investigations related to Seroquel sales and marketing practices. This accounts for $520 million of the $538 million provisions taken in the first nine months, $108 million of which taken in third quarter (see Note 4).
Strong cash flows have reduced net debt by $3,981 million since 31 December 2008.